Cargando…

Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions

Eliglustat is a glucosylceramide synthase inhibitor indicated as a long‐term substrate reduction therapy for adults with type 1 Gaucher disease, a lysosomal rare disease. It is primarily metabolized by cytochrome P450 2D6 (CYP2D6), and variants in the gene encoding this enzyme are important determin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahasrabudhe, Siddhee A., Cheng, Shen, Al‐Kofahi, Mahmoud, Jarnes, Jeanine R., Weinreb, Neal J., Kartha, Reena V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828395/ https://www.ncbi.nlm.nih.gov/pubmed/36056771 http://dx.doi.org/10.1002/cpt.2738

Ejemplares similares

Modeling potential interactions between oral Gaucher disease treatment and investigational COVID-19 therapies
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2021)

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats
por: Wang, Qiong, et al.
Publicado: (2019)

N-acetylcysteine Pharmacology and Applications in Rare Diseases—Repurposing an Old Antioxidant
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2023)

Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

Patients with Gaucher disease display systemic oxidative stress dependent on therapy status
por: Kartha, Reena V., et al.
Publicado: (2020)

Suicidal attempt with eliglustat overdose
por: Nadler, Johannes, et al.
Publicado: (2022)

Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells
por: Cheng, Shen, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
por: Callegari, Ernesto, et al.
Publicado: (2020)

Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system
por: Kim, Sarah, et al.
Publicado: (2022)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
por: Komada, Naoto, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Profile of eliglustat tartrate in the management of Gaucher disease
por: Sechi, Annalisa, et al.
Publicado: (2016)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Publicado: (2016)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
por: Bennett, Lunawati L, et al.
Publicado: (2015)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
por: Hanke, Nina, et al.
Publicado: (2021)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
por: Ngo, Lien Thi, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
por: Choi, Min-Koo, et al.
Publicado: (2021)

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs
por: Dong, Zhongqi, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
por: Britz, Hannah, et al.
Publicado: (2020)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
por: Yu, Zhiheng, et al.
Publicado: (2022)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease [Corrigendum]
Publicado: (2015)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications
por: Sun, Lei, et al.
Publicado: (2023)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
por: Tod, M, et al.
Publicado: (2017)

Investigating Transporter‐Mediated Drug‐Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin
por: Wang, Q, et al.
Publicado: (2017)

Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach
por: Schaller, Stephan, et al.
Publicado: (2021)

2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects
por: Choules, Mary P, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4dgt2d8qnqfdar243o6r6pokuk